Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 28, Issue 5, 2010, Pages 866-871

  Toffoli, Giuseppe ^a   Cecchin, Erika ^a   Gasparini, Giampiero ^a   D'Andrea, Mario ^a   Azzarello, Giuseppe ^a   Basso, Umberto ^a   Mini, Enrico ^a   Pessa, Sergio ^a   De Mattia, Elena ^a   Re, Giovanni Lo ^a   Buonadonna, Angela ^a   Nobili, Stefania ^a   De Paoli, Paolo ^a   Innocenti, Federico ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FLUOROURACIL; FLUOROURACIL PLUS LEUCOVORIN; FOLINIC ACID; IRINOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; IFL PROTOCOL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE ESCALATION; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENOTYPE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; COLORECTAL TUMOR; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATIENT SELECTION; PHENOTYPE; RISK ASSESSMENT; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; LOGISTIC MODELS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATIENT SELECTION; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 77649210559     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.6125     Document Type: Article

References (33)

1. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000 (Pubitemid 30162806)
2. Köhne CH, van Cutsem E, Wils J, et al: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856-4865, 2005
3. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
4. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144-145, 2001
5. van Cutsem E, Douillard JY, Kohne CH: Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 345:1351-1352, 2001
6. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
7. Ducreux M, Ychou M, Seitz JF, et al: Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 17:2901-2908, 1999 (Pubitemid 29415251)
8. Biason P, Masier S, Toffoli G: UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J Chemother 20:158-165, 2008 (Pubitemid 351797053)
9. Hoskins JM, Goldberg RM, Qu P, et al: UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst 99:1290-1295, 2007 (Pubitemid 47394168)
10. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004 (Pubitemid 41103619)
11. Kim TW, Innocenti F: Insights, challenges, and future directions in irinogenetics. Ther Drug Monit 29:265-270, 2007 (Pubitemid 47262254)
12. Toffoli G, Cecchin E, Corona G, et al: The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061-3068, 2006
13. U S Food and Drug Administration: Irinotecan package insert. http://www.fda.gov/ohrms/dockets/dockets/05p0496/05p-0496-cp00001-04-Attachment- 03-vol1.pdf
14. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
15. Bosma PJ, Chowdhury JR, Bakker C, et al: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175, 1995
16. Monaghan G, Ryan M, Seddon R, et al: Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347:578-581, 1996 (Pubitemid 26070740)
17. Iyer L, Das S, Janisch L, et al: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47, 2002 (Pubitemid 34982202)
18. Marcuello E, Altes A, Menoyo A, et al: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678-682, 2004 (Pubitemid 39141623)
19. Rouits E, Boisdron-Celle M, Dumont A, et al: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159, 2004 (Pubitemid 39099790)
20. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95:8170-8174, 1998
21. Iyer L, Hall D, Das S, et al: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582, 1999
22. Ramírez J, Mirkov S, Zhang W, et al: Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J 8:152-161, 2008
23. Marcuello E, Paré L, Paé z Lopé z-Bravo D, et al: A genotype-based dose-escalation study of irinotecan in advanced colorectal cancer patients treated in second-line of chemotherapy. J Clin Oncol 26: 635s, 2008 (suppl; abstr 14599)
24. Innocenti F, Janisch L, Das S, et al: A genotype-directed phase I study of irinotecan in advanced cancer patients. J Clin Oncol 25:97s, 2007 (suppl; abstr 2502)
25. Merrouche Y, Extra JM, Abigerges D, et al: High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study. J Clin Oncol 15:1080-1086, 1997
26. Van Cutsem E, Dirix L, Van Laethem JL, et al: Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: Results from a multinational, randomised phase II study. Br J Cancer 92:1055-1062, 2005
27. Ychou M, Raoul JL, Desseigne F, et al: High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol 50:383-391, 2002
28. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875, 2005
29. André T, Louvet C, Maindrault-Goebel F, et al: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer: GERCOR. Eur J Cancer 35:1343-1347, 1999
30. Chabot GG, Abigerges D, Catimel G, et al: Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141-151, 1995
31. Han JY, Lim HS, Shin ES, et al: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237-2244, 2006
32. Cecchin E, Innocenti F, D'Andrea M, et al: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27:2457-2465, 2009
33. Innocenti F, Kroetz DL, Schuetz E, et al: Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27:2604-2614, 2009